Monday, 09 December 2019

PeptiDream announces new PDC collaboration with Novartis

28 June 2019 | News

Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of novel macrocyclic/constrained peptides for use as Peptide-Drug Conjugates (PDCs) against multiple targets of interest selected by Novartis

Image Courtesy: pciaw

Image Courtesy: pciaw

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, on 27 June 2019, announced a new Peptide Drug Conjugate “PDC” collaboration agreement with Swiss-based Novartis. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of novel macrocyclic/constrained peptides for use as PDCs against multiple targets of interest selected by Novartis. Novartis will have exclusive rights to the program peptides for radionuclide payloads/conjugates and certain small molecule payloads/conjugates, for both therapeutic and diagnostic uses.

Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, R&D funding payments, and is eligible to receive additional pre-clinical, clinical, approval, and commercial sales milestones, as well as royalties on future sales of any commercialized products resulting from the collaboration.

The long-standing macrocyclic peptide discovery alliance between the companies was originally initiated in 2012 and has been extended/amended/expanded multiple times since, including a non-exclusive license to PeptiDream’s PDPS technology in 2015.

 “We are extremely excited to be working with Novartis on peptide drug conjugates, specifically on peptide-radionuclide conjugates, in which Novartis is one of the leading companies in the space. Our macrocyclic/constrained peptides are ideal for the delivery of conjugated payloads, either therapeutic or diagnostic, specifically to the targeted cells/tissues and we believe this partnership has the potential to bring a number of first-in-class and best-in-class therapeutics and their companion diagnostics to patients worldwide” said Patrick Reid, CEO of PeptiDream Inc.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is APAC region emerging as a leader in assistive technologies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls